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Abstract
Cdc2-like kinases (CLKs) represent a family of serine-threonine kinases involved in the regula-
tion of splicing by phosphorylation of SR-proteins and other splicing factors. Although com-
pounds acting against CLKs have been described, only a few show selectivity against dual-
specificity tyrosine phosphorylation regulated-kinases (DYRKs). We here report a novel CLK
inhibitor family based on a 6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one core scaffold. Within the
series, 3-(3-chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (KuWal151) was identified
as inhibitor of CLK1, CLK2 and CLK4 with a high selectivity margin towards DYRK kinases.
The compound displayed a potent antiproliferative activity in an array of cultured cancer cell
lines. The X-ray structure analyses of three members of the new compound class co-crystal-
lized with CLK proteins corroborated a molecular binding mode predicted by docking studies.
Introduction
Splicing is a major regulator in the process of protein biosynthesis during which pre-mRNA is
modified at the spliceosome. Introns are removed and exons reconnected within the nucleus
to form the final mRNA which is then translocated to the cytoplasm and translated into the
respective amino acid sequence at the ribosomes. By reconnecting different exons, multiple
mRNA sequences are generated originating from the same gene leading to different isoforms
of a specific protein, with different and sometimes opposing functions. This alternative splic-
ing process is tightly regulated by various proteins, such as protein kinases, and is observed for
approximately 95% of genes consisting of multiple exons [1,2]. Dysregulation in splicing has
been identified as a relevant contributor to the development of diseases [3], e.g. neurodegener-
ative disorders such as Alzheimer’s disease [4,5]. Alternative splicing is often a regulatory
mechanism which may result in translation of proteins with different function. For instance,
splicing of vascular epithelial factor is regulated by kinases of the SRPK family. The inhibition
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of SRPK1 results in predominant expression of antiangiogenic VEGF isoforms, a phenotypic
response that has been exploited for the development of SRPK inhibitors for treatment of mac-
ular degeneration [6,7].
In various cancers, alternative splicing has been shown to contribute to survival of tumor
cells by suppression of apoptosis [8], to cancer cell migration and adhesion [9], and to resis-
tance against antitumor drugs [10,11]. In this context, the use of small molecules modulating
the splicing machinery has been suggested as therapeutic option in cancer therapy [12].
The human splicing factor SPF45 is overexpressed in various cancer tissues and is involved
in the formation of drug-resistant tumor cells [13]. The protein kinase CLK1 (cdc2-like
kinase1) modulates activity of SPF45 by regulating its expression and by phosphorylating the
protein at distinct serine residues [14]. The observation that siRNA-induced knockdown of
CLK1 leads to SPF45 degradation suggests the use of small molecular CLK1 inhibitors as anti-
cancer drugs [14].
The CLK protein kinase family is closely related both in structure and function to the family
of dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs). Sequence homology
between CLK1 (PDB-ID: 1Z57) and DYRK2 (PDB-ID: 4AZF) was determined to be 55% (36%
identity) according to the Blast algorithm applied through the protein data bank interface [15].
The DYRK kinases, especially DYRK1A, have been associated with mental retardation in
Down syndrome as well as Alzheimer’s disease and are also involved in the regulation of splicing
[16–19]. If inhibitors are used in biochemical assays to study the role of either CLKs or DYRKs,
selective reagents are needed for an accurate differentiation between the specific kinase effects.
The ATP binding pockets of CLK1 and DYRK1A are rather similar both in terms of sequence
and surface shape. In both kinases the gatekeeper (gk) residue is a phenylalanine, and also the
three following amino acids are identical (gk+1; gk+3) or similar (gk+2: leucine in CLK1 and
methionine in DYRK1A). Given the structural similarity of the two kinase families, the design
of specific and potent ATP-competitive inhibitors is a challenging task. Several small molecules
(Fig 1) have been reported as concomitant inhibitors of both the CLK and the DYRK kinase
families [20,21]. The CLK inhibitor TG003 (1) [22] was frequently used in biological studies. In
a kinase binding assay reported by Mott et al., TG003 showed comparable Kd values against
CLK1 (19 nM) and against DYRK1A (12 nM) [23]. Within a series of quinazoline derivatives,
the compound NCGC00185963 (2) was reported to exhibit moderate selectivity for CLK1 versus
DYRK1A (IC50 CLK1: 96 nM; DYRK1A 206 nM). A kinome wide binding assay showed that 2
interacted only with protein kinases of the CMGC family [24]. The potent CLK1 inhibitor
KH-CB19 (3) displayed also activity against DYRK1A (IC50 CLK1: 20 nM; DYRK1A 55 nM)
[25]. Until recently it was a matter of debate whether the design of truly selective inhibitors for
either kinase would be possible. In 2015 the first potent DYRK1A inhibitor with substantial
selectivity versus CLK1 was published [26]. The benzo[b]thiophen-2-carboxamide 4 was
reported as potent CLK1 inhibitor with considerable selectivity versus DYRK1A (IC50 CLK1: 7
nM; DYRK1A 340 nM) [27]. Consistent with the modulation of SP45 activity by CLK1 and ear-
lier findings that CLK inhibitors induce apoptosis and show antitumor activity in vitro [28], 4
inhibited the growth of certain cancer cell lines at submicromolar concentrations [27]. Com-
pound T3 (5) was disclosed as a subnanomolar CLK1 inhibitor, displaying selectivity versus
DYRK1A of more than three orders of magnitude (IC50 CLK1: 0.67 nM; DYRK1A 260 nM). In
line with its potent CLK inhibition, 5 inhibited the growth of a colorectal cancer cell line at sub-
micromolar concentrations (GI50 HCT116: 130 nM) [29]. The CLK inhibitor TG693 (6) modu-
lates the mutated exon 31 of the dystrophin gene in mice, and might be a suitable starting point
for the development of therapeutics against the Duchenne muscular dystrophy (DMD). 1 μM
TG693 inhibited the activities of DYRK1A by 84% and of CLK1 by 93%, exhibiting some selec-
tivity for the latter enzyme [30]. Recently, the [1,2,3]triazolo[4,5-c]quinoline 7 was reported as
Structures of CLK/inhibitor complexes
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potent and selective CLK1 inhibitor, inducing autophagy in vitro and showing hepatoprotective
effects in vivo in an acetaminophen-induced liver injury mouse model [31]. We here report
6,7-dihydropyrrolo[3,4-g]indol-8(1H)-ones as another class of CLK inhibitors. A distinct repre-
sentative of this compound family, 3-(3-chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-
one (KuWal151, 8c), exhibited selectivity versus DYRK1A and other DYRK kinases and showed
potent antiproliferative activity against a broad panel of in vitro cultured cancer cell lines.
Screening campaign for CLK inhibitors
The novel protein kinase inhibitor family of 6,7-dihydropyrrolo[3,4-g]indol-8(1H)-ones was
discovered during a screening campaign of an in house compound library for CLK inhibition
by radiometric in vitro kinase assays. In order to assess selectivity, activities on other kinases of
the CMGC group besides CLKs (CDK1/cyclin B, CDK2/cyclin A, CDK5/p25, CDK9/cyclin T,
CK1, DYRK1A, DYRK1B, DYRK2, DYRK3, GSK-3β) were tested as well. While the 3-substi-
tuted derivative 8a was identified as a slightly selective inhibitor of CLK1, some 2,3-disubsti-
tuted congeners and a 6-oxo derivative were less active or not as selective versus casein kinase
1 (CK1) and against DYRKs (S1 Table). To our best knowledge, 6,7-dihydropyrrolo[3,4-g]
Fig 1. CLK1 inhibitors described in the literature. TG003 (1); NCGC00185963 (2), KH-CB19 (3); benzo[b]thiophen-2-carboxamide 4; T3
(5); TG693 (6); [1,2,3]triazolo[4,5-c]quinoline 7.
https://doi.org/10.1371/journal.pone.0196761.g001
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indol-8(1H)-ones like 8a unsubstituted at the 6- or 7-position have not been published before.
Comprising a pyrrole unit connected to a γ-butyrolactam ring via a double bond, 8a is struc-
turally related to the GSK-3/CDK inhibitor indirubin (9a) [32–34](Fig 2).
Molecular docking
Via in silico molecular docking, candidates for the synthesis of 8a-related derivatives were
designed based on the predicted binding mode of the basic heterocyclic scaffold in the ATP-
binding pocket of CLK1 (PDB-ID: 1Z57). The docking tool GOLD [35] was used to fit the
inhibitor 8a into the ATP binding pocket of a published CLK1 crystal structure (PDB-ID:
1Z57 [36]) (Fig 3). Based on this prediction, the pyrrolinone moiety of 8a is oriented towards
the hinge region forming two hydrogen bonds, one being established between gk+1 (Glu242)
and the NH of the ligand and a second via the carbonyl oxygen to Leu244 (gk+3). The indole
nitrogen is not involved in direct hydrogen bonding to the hinge region. The planar heterocy-
clic core scaffold is positioned in the adenine pocket of the binding site. At the entrance of the
ATP pocket, the 3-phenyl substituent is situated establishing an edge to face interaction [37]
with Phe172 of the p-loop. From the top view it becomes visible that the binding site is not
filled completely by 8a, offering further possibilities for additional hydrogen bonding, for
example to Asp250 which could be addressed by polar substituents at the phenyl ring. More-
over, there is some unoccupied space in the back of the binding site towards the gatekeeper
Phe241 which could be filled by substituents of moderate size at position 5.
Based on the outcome of the docking studies with 8a, analogues were designed with the
intention of creating ligands with improved CLK inhibitory potency and selectivity versus
other kinases. For example, docking of the 3-hydroxyphenyl derivative 8g predicted the forma-
tion of a hydrogen-bond between the hydroxyl group and Asp250 of CLK1, so that an increase
in affinity was expected. Introduction of halogens at position 5 of the parent ring system led to
Fig 2. Hit compound 8a identified as CLK1 inhibitor in a library screening and the structurally related dye
indirubin (9a). Both compounds comprise a pyrrole unit connected to a γ-butyrolactam ring via a double bond.
https://doi.org/10.1371/journal.pone.0196761.g002
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analogues 12a-c, which were predicted to occupy previously unused space in the binding
pocket. Larger substituents in the 5-position (analogues 17a-c) appeared too big for this area,
but were also prepared for means of comparison. Alkylation at the indole nitrogen with short
chains did not alter the predicted binding mode and were introduced with the aim to enable
additional contacts with the protein. On the other hand, a substitution at the nitrogen in posi-
tion 7 led to derivatives for which the docking studies were unable to reproduce the binding
mode suggested for 8a and which were expected to show reduced kinase inhibitory activity.
Chemistry
Starting from commercially available 7-aminoisoindolin-1-one 10a, the arylhydrazines 11a-d
were prepared as central building blocks for the construction of the 6,7-dihydropyrrolo[3,4-g]
indol-8(1H)-one core scaffold. Introduction of halogen substituents at position 4 of the 7-ami-
noisoindolin-1-one was achieved by reaction with N-bromosuccinimide (NBS) or N-chloro-
succinimide (NCS), respectively. A selective methylation of 10a at the pyrrolidinone nitrogen
was accomplished with iodomethane and potassium tert-butylate in THF furnishing 10d [38].
Reaction of 10a-d with sodium nitrite and hydrochloric acid yielded the corresponding diazo-
nium chlorides which were directly reduced to the hydrazinium chlorides 11a-d. Heating in
acetic acid with suitable aldehydes or ketones yielded the 3-phenyl-6,7-dihydropyrrolo[3,4-g]
indol-8(1H)-one derivatives 8 as products of a Fischer indole reaction. Due to the formation of
numerous side products, extensive purification processes were necessary to obtain clean prod-
ucts which in turn led to low yields. Especially the 2-phenylacetaldehyde derivatives proved to
be very unstable during the reaction as well as under storage conditions. Aliphatic aldehydes
in general are known to form adducts or polymers by self-condensation. It has been previously
described that 2-phenylacetaldehydes are particularly prone to degradation because of the acti-
vated methylene group between carbonyl group and aromatic ring [39]. Therefore, the com-
mercially available dimethyl acetal of 2-phenylacetaldehyde was used as a more stable
substitute for the free aldehyde in the synthesis of 8a. As exemplified for the synthesis of 8f, the
adaption of a method published by Grubbs et al. [40] offered the possibility to avoid handling
of the aldehydes by oxidation of styrenes, directly reacting the in situ-formed aldehydes in the
Fischer indole ring closure. The phenol derivative 8g was prepared by boron tribromide-pro-
voked ether cleavage of the methoxy derivative 8f [41]. Subsequent treatment with acetic acid
anhydride yielded the ester 8h. Alkyl substituents at the indole nitrogen were introduced after
Fig 3. Results of a docking experiment with 8a in CLK1 (PDB-ID: 1Z57). A: front view; B: top view; dashed lines: H-bonds and edge to face
interaction.
https://doi.org/10.1371/journal.pone.0196761.g003
Structures of CLK/inhibitor complexes
PLOS ONE | https://doi.org/10.1371/journal.pone.0196761 May 3, 2018 5 / 29
formation of the indole ring system by reaction of alkyl halides with 8a in the presence of
potassium tert-butylate using acetone as solvent. The choice of solvent is essential for a selec-
tive alkylation at the indole nitrogen in the presence of secondary lactam groups [38]. How-
ever, methylation at both nitrogen atoms of 8a was observed when iodomethane was
employed as alkylating reagent, leading to the formation of side product 15e in significant
amounts. The 2-brominated derivative 16 was prepared by reaction of 8a with N-bromosucci-
nimide. Eventually, the 5-aryl substituted derivatives 17a-c were synthesized by a microwave-
assisted Suzuki-Miyaura coupling of 12a with arylboronic acids (Fig 4) [42]. The compounds
prepared by these methods are represented by the general formula depicted in Fig 5 and are
listed in Table 1.
Crystal structure analysis
To enable experimental analyses of the molecular interaction between 3-aryl-6,7-dihydropyrrolo
[3,4-g]indol-8(1H)-ones and their target enzymes, co-crystallization experiments with some repre-
sentative congeners and CLK1 or CLK3 were carried out, respectively. From these approaches,
8g/CLK1, 12a/CLK1 and 8a/CLK3 were generated as crystalline inhibitor/protein complexes. The
X-ray crystal structure analyses corroborated the general binding mode predicted by the docking
studies. For instance, in the complex of CLK1 with the hydroxy compound 8g (PDB-ID: 6FT8),
the ligand forms two hydrogen bonds to the hinge region (Glu242, Leu244). The predicted addi-
tional H-bond to Asp250 is formed via the hydroxyl group of the inhibitor. Furthermore, the
indole nitrogen indirectly establishes H-bonds to the hinge region through a water molecule
which interacts with the carbonyl oxygens of Leu244 and Gly245 (Fig 6A). A comparison of the
8g/CLK1 crystal structure (Fig 6A) with indirubin-5-sulphonate (9b, Fig 6D) cocrystallized with
CDK2 (Fig 6C) [43] demonstrates similar binding modes. Both ligands contain pyrrolinone scaf-
folds which are involved via the nitrogen NH and the carbonyl oxygen in hydrogen bonds to the
hinge region amino acids gk+1 and gk+3. In contrast to the pyrrole-annulated isoindolinone 8g,
indirubins such as 9b consist of two indolinone elements connected by a double bond. Neverthe-
less, in both crystal structures one of the two NH groups is oriented towards the leucine of the
hinge region (gk+3). However, only the indirubin derivative is positioned close enough to estab-
lish a direct H-bond to the gk+3 residue (Leu83 in the case of CDK2), whereas for the indole
nitrogen of 8g indirect bonding via a water molecule to the corresponding Leu244 of CLK1 is
observed. The sulphonate substituent at position 5 of the indirubin derivative 9b is involved in a
further hydrogen bond to the conserved lysine of CDK2, increasing its potency compared to
indirubin (IC50 CDK2 9b: 35 nM) [43]. In contrast, 8g is anchored within the ATP-pocket by an
additional H-bond between the hydroxyl group and Asp250. As the DYRK kinases are structurally
closely related to the CLK family, assessment of inhibitor selectivity against DYRKs is relevant. Fig
6B shows the potential binding mode of 8g in DYRK1A (PDB-ID: 3ANQ) [44] resulting from a
docking analysis. The general orientation is very similar to the one observed in the CLK1 cocrystal
structure. Between the lactam function of the inhibitor and the gk+1 and gk+3 residues of the pro-
tein two hydrogen bonds are formed, respectively. An increase in the distance of the indole nitro-
gen to the hinge region, caused by a horizontal shift of the ligand, prevents the formation of a
direct H-bond as observed for indirubin. Moreover, due to this shift the position of the phenol at
the entrance of the ATP-binding site is changed as well. Instead of hydrogen bonding between the
hydroxyl group and Asp247, an interaction with the backbone amide of Lys167 is predicted.
Although the hit structure 8a from the initial screening failed to inhibit CLK3 at concentra-
tions below 10 μM, we were able to crystallize this protein kinase in complex with the ligand
(PDB-ID: 6FT7). The X-ray structure analysis revealed that the inhibitor is localized in the
ATP binding pocket, occupying a position similar to the binding mode predicted by the
Structures of CLK/inhibitor complexes
PLOS ONE | https://doi.org/10.1371/journal.pone.0196761 May 3, 2018 6 / 29
docking study for the pose in CLK1. As observed in the 8g/CLK1 complex, the lactam element
of 8a establishes hydrogen bonds to the gk+1 and the gk+3 amino acids of CLK3, and the
indole nitrogen forms a water-mediated hydrogen-bond to the hinge region (Fig 7). Compared
to the situation of 8g in CLK1, 8a is slightly rotated in the binding pocket of CLK3 so that the
Fig 4. Synthesis procedures for 3-aryl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-ones. For residues R1-R5 refer to Table 1. Reagents and conditions: (reagents and
conditions a, for synthesis of 10b) NBS, CH2Cl2, - 8˚C, 1 h, 78%; (reagents and conditions b, for synthesis of 10c) NCS, acetonitrile, 60˚C! reflux, 2 h, 81%; (reagents
and conditions c, for synthesis of 10d) CH3I, KOtBu, THF, RT, N2, 24 h, 54%; (d) 1. 37% HCl, NaNO2,< 0˚C; 2. 37% HCl, SnCl2 x 2 H2O, 30 min; (e) aldehyde or ketone
or acetal, acetic acid, 95˚C, 3.5 h, 10%-31%; (f) PdCl2(MeCN)2, p-benzoquinone, tert-butanol, water, 80˚C; (g) 11a, ethanol, H2SO4, H2O, 50˚C, 2.5 h, 23%; (h) BBr3,
CH2Cl2, RT, N2, 1 h, 33%; (i) acetic anhydride, pyridine, 4-DMAP, RT, 3 h, 29%; (j) alkyl halide, KOtBu, acetone, RT, N2, 24 h, 15%-48%; (k) NBS, CH2Cl2/acetic acid,<
10˚C, N2, 1.5 h, 29%; (l) appropriate arylboronic acid, Cs2CO3, toluene/ethanol, mircowaves, 150˚C, 20 min, 5.4%-31%.
https://doi.org/10.1371/journal.pone.0196761.g004
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indole nitrogen is veered away from the hinge region and the phenyl substituent is shifted
slightly towards the DFG motif. The cavity near the αC-helix and the DFG motif is not occu-
pied by the ligand, but by an ethylene glycol molecule which is kept in place by hydrogen
bonds to the canonical Lys186 and Asp320 of the DFG motif. In further inhibitor design
approaches this region of the binding pocket could be addressed by tailored side chains sprout-
ing from the core element of new ligands.
Fig 5. 3-Aryl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-ones listed in Table 1.
https://doi.org/10.1371/journal.pone.0196761.g005
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A third crystallized inhibitor/ligand complex was generated from the 2-bromo-substituted
analogue 16 with CLK1 (PDB-ID: 6FT9). The structure analysis revealed a binding mode
resembling the orientations of 8g in CLK1 and of 8a in CLK3. While the lactam substructure
of 16 forms hydrogen bonds to the hinge region, the indole nitrogen is connected to the hinge
via hydrogen bonds through a water molecule. The planes of the phenyl substituents in 8g and
16 are nearly perpendicularly oriented in the two structures. In both complexes, three water
molecules occupy the area near the Lys191 and Glu206 side chains. For accommodation of the
bromo substituent of 16, the entrance to the ATP pocket is somewhat widened compared to
the situation found with 8g (Fig 8).
Although by means of selectivity congener 8c appears to be the most interesting representa-
tive of the series, a crystallized complex with CLK1 or one of the other protein kinases men-
tioned above was not generated up to now. S1 Fig in the supporting information illustrates the
putative binding mode of this molecule in CLK1, resulting from a docking experiment.
Biological evaluation and discussion
The synthesized derivatives of 8a were evaluated in a panel of CMGC kinases as summarized
in Table 1. 8j, containing a 3-nitro group at the phenyl substituent, was the most potent CLK1
inhibitor in the series 8. Similar other derivatives with small substituents at the phenyl rings
Table 1. Structures of and CMGC kinase inhibition by 3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-ones (IC50-values [μM])a.
R1 R2 R3 R4 R5 CDK1/
cyclin B
CDK2/
cyclinA
CDK5/
p25
CDK9/
cyclin T
CK1 CLK
1
CLK
2
CLK
3
CLK
4
DYRK
1A
DYRK
1B
DYRK
2
DYRK
3
GSK3
8a H H H H H > 10 > 10 > 10 > 10 > 10 0.046 0.21 > 10 0.12 > 10 4.8 0.72 > 10 > 10
8b 2-Cl H H H H > 10 > 10 > 10 > 10 > 10 0.14 nd nd nd 1.1 nd nd nd > 10
8c 3-Cl H H H H > 10 > 10 > 10 > 10 > 10 0.088 0.51 > 10 0.028 > 10 > 10 > 10 > 10 > 10
8d 4-Cl H H H H > 10 > 10 > 10 > 10 > 10 0.10 0.17 1.8 0.13 > 10 > 10 9.3 > 10 > 10
8e 3,4-dichloro H H H H > 10 > 10 > 10 > 10 > 10 0.11 0.69 > 10 0.13 > 10 > 10 > 10 > 10 > 10
8f 3-OCH3 H H H H > 10 > 10 > 10 > 10 > 10 0.11 0.32 2.8 0.11 3.8 1.9 2.1 5.4 > 10
8g 3-OH H H H H > 10 > 10 > 10 1.1 > 10 0.044 0.082 1.7 0.081 0.74 0.39 0.59 2.2 > 10
8h 3-OCOCH3 H H H H > 10 > 10 > 10 > 10 > 10 0.17 0.32 3.3 0.13 1.4 1.5 2.4 6.1 > 10
8i 3-CH3 H H H H > 10 > 10 > 10 > 10 > 10 0.061 0.41 5.1 0.14 2.6 4.1 3.1 > 10 > 10
8j 3-NO2 H H H H > 10 > 10 > 10 > 10 > 10 0.038 0.37 8.5 0.061 > 10 1.5 4.9 1.9 > 10
8k H H H H CH3 > 10 > 10 > 10 > 10 > 10 0.093 nd nd nd 1.5 nd nd nd > 10
8l H H H H C2H5 > 10 > 10 > 10 > 10 6.1 0.12 nd nd nd 0.81 nd nd nd > 10
12a H Br H H H 2.8 > 10 5.3 > 10 1.7 0.043 nd nd nd 0.20 nd nd nd > 10
12b H Br H H CH3 > 10 > 10 > 10 > 10 > 10 0.023 0.025 7.1 <
0.03
0.11 0.11 0.11 0.12 > 10
12c H Cl H H H nd > 10 > 10 > 10 > 10 0.38 0.033 2.2 0.3 0.32 1.8 2.3 > 10 > 10
12d H H CH3 H H > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10
15a H H H CH3 H > 10 > 10 > 10 > 10 > 10 0.19 1.1 > 10 0.16 > 10 > 10 > 10 > 10 > 10
15b H H H C2H5 H > 10 > 10 > 10 > 10 > 10 0.38 nd nd nd 3.9 nd nd nd > 10
15c H H H CH2CONH2 H > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10
15d H H H CH2COOC2H5 H > 10 > 10 > 10 > 10 > 10 > 10 nd nd nd > 10 nd nd nd > 10
15e H H CH3 CH3 H > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10
16 H H H H Br > 10 > 10 > 10 > 10 > 10 0.11 0.11 2.8 0.029 1.9 1.3 1.8 3.9 > 10
17a H Ph H H H > 10 > 10 > 10 > 10 > 10 8.8 7.2 > 10 1.3 > 10 > 10 > 10 > 10 > 10
17b H 2-F-Ph H H H > 10 > 10 > 10 > 10 > 10 5.8 4.1 > 10 0.91 > 10 > 10 > 10 > 10 > 10
17c H 3-F-Ph H H H > 10 > 10 > 10 > 10 > 10 7.2 > 10 > 10 3.2 > 10 > 10 > 10 > 10 > 10
a IC50 values below 1 μM are highlighted in bold. All data points for construction of dose response curves were recorded in triplicate. Typically, the standard deviation of
single data points was below 10%. nd: not determined.
https://doi.org/10.1371/journal.pone.0196761.t001
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exhibited activity in the same order of magnitude. However, the substitution pattern on the
3-phenyl ring influenced the CLK/DYRK selectivity profile. In case of the 3-hydroxy derivative
Fig 6. Crystal structures of inhibitor-kinase complexes. A: Co-crystal structure of 8g in CLK1 (PDB-ID: 6FT8). B: Docking pose of 8g in
DYRK1A (PDB-ID: 3ANQ [44]). C: Co-crystal structure of indirubin-5-sulphonate (9b) in CDK2 phosphorylated at Thr160 (PDB-ID: 1E9H
[43]). D: Indirubin-5-sulphonate 9b.
https://doi.org/10.1371/journal.pone.0196761.g006
Fig 7. Cocrystal structure of 8a with CLK3 (PDB-ID: 6FT7); red spheres: water molecules; EG: Ethylene glycol;
black dashed lines: hydrogen bonds. A: The lactam motif of the ligand forms the canonical hydrogen bonds to the
amino acids gk+1 (Glu237) and gk+3 (Leu239); the indole nitrogen is connected to the amino acid gk+4 (Gly240). B:
Side view. An ethylene glycol molecule fills a space at the back of the pocket near the αC-helix which is left unoccupied
by 8a.
https://doi.org/10.1371/journal.pone.0196761.g007
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8g, the changes may be attributable to the additional hydrogen bond formed between the phe-
nol OH-group and Asp250 (Fig 6A). Low selectivity as well as reduced activity was observed
for the larger acetyloxy substituent in 8h. Compared to the unsubstituted 8a, introduction of
chloro substituents in 3- or 4-position at the phenyl ring caused a loss of activity but improved
CLK1 versus DYRK selectivity (8c-e). In contrast, a 2-Cl substituent (8b) proved to be disad-
vantageous in this respect. The overall observation that in series 8 nature and position of the
substituents at the 3-phenyl ring produced only a minor effect on CLK1 inhibitory activity cor-
responds well to its position at the opening of the ATP-binding site. Methylation of the indole
nitrogen atom (15a) led to a minor loss of CLK1 inhibitory activity whereas methylation at the
lactam nitrogen (12d) resulted in complete inactivity, underlining the importance of the hy-
drogen donor ability of this position for binding affinity. The size of the substituent at the
indole nitrogen (R4 in Table 1) is restricted, because activity is significantly reduced in the
presence of an ethyl substituent (15b) and no longer detected upon acetamide substitution
(15c) or the larger acetic acid ethyl ester (15d). Regarding substitution at position 5 at the het-
erocyclic core the IC50-values were consistent with the predictions from docking studies. The
Fig 8. Comparison of co-crystal structures of 8g (PDB-ID: 6FT8; upper row) and 16 (PDB-ID: 6FT9; lower row) in complex with CLK1,
respectively; red spheres: water molecules; black dashed lines: hydrogen bonds. A: Top view of 8g. B: Side view of 8g. C: Top view of 16. D:
Side view of 16. A, C: While the lactam motives of the ligands perform the canonical hydrogen bonds to the hinge region, the indole nitrogen
atoms are connected to a conserved water molecule. B, D: An area near the Lys191 and Glu206 side chains, unoccupied by both 7g and 16, is
filled by three water molecules. The opening to the entrance of the binding pocket is delimited by Asp250. Compared to the shape of the pocket
with bound 8g (B), the entrance of the binding pocket is widened to accommodate the 2-bromo substituent of 16 (D).
https://doi.org/10.1371/journal.pone.0196761.g008
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bromo-substituent of 12a occupies previously unused space in the back pocket. This feature
leads to retained activity on CLK1 (IC50 CLK1: 43 nM) on the one hand, but diminished selec-
tivity towards DYRK1A and other tested kinases on the other hand. While the additional
2-methyl substituent in 12b maintained selectivity towards CDK1, CDK5 and CK1, this conge-
ner is still a potent inhibitor of DYRK1A. The observation that the 5-phenyl substituents pres-
ent in the derivatives 17a-c are not tolerated without loss of CLK inhibitory activity is well
explained by the lack of space in the back pocket for accommodation of these large residues.
Substitution of the parent structure 8a at position 2 by either methyl (8k) or bromine (16)
decreased the selectivity towards the DYRK family more than tenfold. A further loss of selec-
tivity towards CK1 was observed with the larger ethyl substituent (8l), although the CLK1
inhibitory activity was not significantly deteriorated. The selectivity profile of the compound
class within the CLK family revealed a parallel change of IC50 values for CLK1 and CLK4 upon
substitution pattern variation at the heterocyclic core scaffold of 8a. With the exception of 12c,
inhibitory activity on CLK2 was found to be in the same order of magnitude, but consistently
lower than on CLK1 and CLK4. In contrast, all congeners showed considerably weaker or lack-
ing inhibition of CLK3. Overall, the biological data shows that it is possible to avoid inhibition
of DYRK kinases and create entirely CLK selective molecules, although with the disadvantage
of losing potency. In this regard compound 8c appears to display an optimal balance, exhibit-
ing double digit nanomolar inhibition of CLK1/4 and inactivity on DYRKs up to 10 μM. Selec-
tivity towards the more distantly related CDKs, CK1 and GSK3 is achievable even without
such a trade-off. Although the inhibitor/CLK complex crystal structure analyses nicely repro-
duced the binding modes predicted by the docking experiments, a straightforward explanation
for the CLK selectivity observed with 8c versus DYRK1A is not yet obvious. Perhaps in the
smaller ATP binding pocket of CLK1 more hydrophobic contacts to the inhibitor can be estab-
lished than in the larger pocket of DYRK1A. However, this explanation is at the moment
highly speculative and not yet proven by X-ray crystal structure analyses results.
Being the most promising compound in terms of CLK1 inhibitory potency and selectivity,
KuWal151 (8c) was tested in the National Cancer Institute cancer cell line screening on 57
tumor cell lines of different tissue origin [45]. With only a few exceptions, KuWal151 inhibited
the growth of most cell lines in submicromolar concentrations. In Table 2 the cancer cell line
inhibition data is listed with the expression rates of SPF45 and CLK1 as indicated in the Expres-
sion Atlas database (https://www.ebi.ac.uk/gxa/home). Apparently the cell lines with high lev-
els of CLK1 encoding RNA are inhibited over average. The cell line MDA-MB-435 which was
most strongly inhibited in the screening panel (GI50 = 72 nM) expresses a comparably high
CLK1-RNA level of 22 FPKM (for an explanation of FPKM, refer to [46]). In contrast, the least
sensitive cell line UACC 257, on which 8c did not reach the GI50 up to 50 μM, has a comparably
low CLK1-RNA level of 12 FPKM. However, the available data are not sufficient to construe a
clear relationship between the expression levels of the putative target CLK1 and sensitivity of
the cell lines against 8c. The same holds true for SPF45, an important substrate of CLK1 inv-
olved in splicing which is found to be overexpressed in many cancer cell lines. While several of
the cell lines with high SPF45 expression levels (HCT-116, HCT-15, HT-29, KM12, MCF-7) are
strongly inhibited by 8c, other (OVCAR-8, HOP-92, MDA-MB-431) were comparably less sen-
sitive to the inhibitor. The lack of a straight relationship between CLK1 and/or SPF45 expres-
sion levels on the one hand and sensitivity against the CLK1 inhibitor 8c on the other hand may
have various reasons, e.g. different uptake rates of the inhibitor by the cells or alternative intra-
cellular targets. For verification of the results from the NCI screening, which is based on the in
situ fixation of cells followed by staining with the protein-binding dye sulforhodamin B [47,48],
8c was also tested on two cell lines of the NCI panel (HT-29 and MDA-MB-231) in a crystal vio-
let assay. The results (S2 Table) showed similar inhibition concentrations with GI50 values in
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Table 2. In vitro growth inhibition of cancer cell lines by KuWal151 (8c)a.
Cell line Cancer origin GI50 [μM] SPF45b [FPKM]c CLK1 [FPKM]c
786–0 Renal Cancer 0.275 18 13
A498 Renal Cancer 0.166 10 9
A549/ATCC Non-Small Cell Lung Cancer 0.389 16 11
ACHN Renal Cancer 0.372 15 6
BT-549 Breast Cancer 0.204 n.a. n.a.
CCRF-CEM Leukemia 0.178 n.a. n.a.
COLO 205 Colon Cancer 0.209 n.a. n.a.
DU-145 Prostate Cancer 0.316 22 7
EKVX Non-Small Cell Lung Cancer 0.355 19 12
HCC-2998 Colon Cancer 0.912 n.a n.a
HCT-116 Colon Cancer 0.191 22 9
HCT-15 Colon Cancer 0.178 25 15
HL-60(TB) Leukemia 0.141 9 14
HOP-92 Non-Small Cell Lung Cancer 5.62 19 7
HS 578T Breast Cancer 0.204 6 8
HT29 Colon Cancer 0.174 19 15
IGROV1 Ovarian Cancer 0.427 21 11
K-562 Leukemia 0.162 18 9
KM12 Colon Cancer 0.209 20 39
LOX IMVI Melanoma 0.245 17 17
M14 Melanoma 0.132 n.a n.a
MCF7 Breast Cancer 0.174 19 11
MDA-MB-231/ATCC Breast Cancer 1.38 18 14
MDA-MB-435 Melanoma 0.0724 11 22
MDA-MB-468 Breast Cancer 0.234 20 11
MOLT-4 Leukemia 0.257 n.a n.a
NCI/ADR-RES Ovarian Cancer 0.178 n.a n.a
NCI-H226 Non-Small Cell Lung Cancer 28.8 8 6
NCI-H23 Non-Small Cell Lung Cancer 0.525 25 12
NCI-H322M Non-Small Cell Lung Cancer 2.39 7 13
NCI-H460 Non-Small Cell Lung Cancer 0.209 15 4
NCI-H522 Non-Small Cell Lung Cancer 0.158 9 15
OVCAR-3 Ovarian Cancer 0.191 12 11
OVCAR-4 Ovarian Cancer 0.912 15 9
OVCAR-5 Ovarian Cancer 1.25 n.a n.a
OVCAR-8 Ovarian Cancer 0.724 36 10
PC-3 Prostate Cancer 0.339 12 15
RPMI-8226 Leukemia 0.288 19 10
RXF 393 Renal Cancer 0.457 n.a n.a
SF-268 CNS Cancer 0.437 12 5
SF-295 CNS Cancer 0.224 11 8
SF-539 CNS Cancer 0.166 12 12
SK-MEL-2 Melanoma 0.316 n.a n.a
SK-MEL-28 Melanoma 0.692 8 12
SK-MEL-5 Melanoma 0.407 9 9
SK-OV-3 Ovarian Cancer 0.275 20 9
SN12C Renal Cancer 0.331 n.a n.a
(Continued)
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the submicromolar range. In this test system, the human adult primary kidney cell line RC-124
was inhibited by comparable concentrations, indicating that splicing inhibition by the CLK
inhibitor KuWal151 (8c) affects non-cancerous cells as well.
Conclusion
3-Aryl-substituted 6,7-dihydropyrrolo[3,4-g]indol-8(1H)-ones were identified as inhibitors of
the CLK protein kinase family. Among the members of this new inhibitor class, KuWal151
(8c) was identified as a CLK1, CLK2 and CLK4 inhibitor with double-digit nanomolar potency
and selectivity versus the closely related protein kinases of the DYRK family. The putative ori-
entation of these inhibitors in the ATP binding pocket of CLK1 proposed by docking studies
was verified by analysis of three crystal structures of closely related analogues of KuWal151 in
complex with CLK1 or CLK3, respectively. In agreement with the binding mode obtained
from the crystal structures and based on the biological data, qualitative structure activity rela-
tionships were established. In submicromolar concentrations 8c displayed a strong antiproli-
ferative activity on most cell lines of the NCI cancer cell line screening panel. Thus, KuWal151
(8c) might be a suitable starting structure for the development of anticancer agents acting on
the splicing machinery of cancer cells.
Experimental
Molecular docking
Prior to the molecular docking experiments the protein crystal structure of CLK1 (PDB-ID:
1Z57) [36] was protonated and stripped of water molecules as well as of the ligand DBQ [49].
All new ligand structures were created and energy minimized in MOE (Molecular Operating
Environment, 2013.08, Chemical Computing Group Inc., Montreal, Canada). GOLD (version
5.2.2.) [35] was used for the docking experiments. The binding site was defined as a sphere
around the cocrystallized ligand DBQ with a radius of 10 Å thus encompassing the ATP-bind-
ing pocket. As a scoring function chemscore [50] was applied with kinase specific parameters
supplied by GOLD. No constraints were added to the setup. Docking accuracy was set to 200%
and early termination was not allowed. The resulting poses were evaluated according to their
Table 2. (Continued)
SNB-19 CNS Cancer 0.389 n.a n.a
SNB-75 CNS Cancer 0.151 10 11
SR Leukemia 0.151 n.a n.a
SW-620 Colon Cancer 0.209 22 17
T-47D Breast Cancer 0.309 20 7
TK-10 Renal Cancer 10.2 n.a n.a
U251 CNS Cancer 0.263 n.a n.a
UACC-257 Melanoma >50.1 8 12
UACC-62 Melanoma 0.275 10 12
UO-31 Renal Cancer 0.832 10 6
a n.a. = not available
b synonym in Expression Atlas: RBM17
c FPKM (fragments per kilobase of exon model per million reads mapped) is a common unit of gene expression
calculated from RNA-sequencing data. The calculation takes into account gene length and total number of mapped
reads [46].
https://doi.org/10.1371/journal.pone.0196761.t002
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score as well as by visual inspection of the respective binding mode. Visualization was carried
out using PyMol, vers. V0.99 [51] (illustrations with green cartoons of host proteins) or using
MOE (Molecular Operating Environment, 2013.08, Chemical Computing Group Inc., Mon-
treal, Canada) (illustrations with brown-and-blue surfaces of host proteins).
Crystallography and structure analysis
CLK1 and CLK3 have been purified as described [36,52]. Crystallization was performed using
sitting-drop vapor diffusion method at 4˚C and various conditions as summarized in Table 3.
Diffraction data were collected at Diamond Light Source and were processed and scaled with
Mosflm [53] and Scala [54], respectively. Structures were solved by molecular replacement
Table 3. Data collection and refinement statistics of CLK/ligand complexes.
Complex CLK1-8g CLK1-16 CLK3-8a
accession code 6FT8 6FT9 6FT7
Data Collection
Beamline Diamond, I04 Diamond, I03 Diamond, I02
Wavelength (Å) 0.97949 0.97624 0.97950
Resolutiona (Å) 23.65–1.45
(1.53–1.45)
29.11–1.87
(1.97–1.87)
59.94–2.02
(2.13–2.02)
Spacegroup C2 P21 P21
Cell dimensions a = 91.6, b = 64.2,
c = 88.4 Å
a = 56.4, b = 116.3, c = 91.3 Å a = 61.8, b = 116.8, c = 69.9 Å
α = γ = 90.0˚, β =
127.7˚
α = γ = 90.0˚, β = 99.0˚ α = γ = 90.0˚, β = 92.8˚
No. unique
reflectionsa
71,117 (10,186) 95,883 (13,962) 62,659 (9,103)
Completenessa (%) 99.1 (97.5) 100.0 (100.0) 96.7 (96.0)
I/σIa 9.9 (2.2) 9.9 (2.0) 8.0 (2.1)
Rmerge
a (%) 0.044 (0.381) 0.083 (0.738) 0.091 (0.668)
Redundancya 3.0 (2.9) 5.2 (5.0) 3.7 (3.6)
Refinement
No. atoms in
refinement (P/L/O)b
2,814/40/484 8,297/120/602 5,896/38/547
B factor (P/L/O)b
(Å2)
25/18/38 42/29/46 43/39/45
Rfact (%) 16.4 16.6 19.2
Rfree (%) 19.5 20.2 23.5
rms deviation bondc
(Å)
0.016 0.016 0.015
rms deviation anglec
(˚)
1.7 1.6 1.6
Molprobity
Ramachandran
Favour (%) 97.92 97.91 96.05
Outlier (%) 0 0 0
Crystallization
conditions
20% PEG3350, 0.1
M sodium
malonate
20% 1,2-propanediol, 10%
glycerol, 0.1 M sodium/potassium
phosphate
21% PEG3350, 0.2 M sodium
iodide, 0.1 M bis-tris-propane pH
7.0, 10% ethylene glycol
a Values in brackets show the statistics for the highest resolution shells.
b P/L/O indicate protein, ligand molecules presented in the active sites, and other (water and solvent molecules),
respectively.
c rms indicates root-mean-square.
https://doi.org/10.1371/journal.pone.0196761.t003
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method using Phaser [55] and the coordinates of published CLK1 and CLK3 structure [36,52].
Model rebuilding was performed in COOT [56] and the structures were refined using REFMAC
[57]. Geometric correctness was verified using MOLPROBITY [58]. The data collection and
refinement statistics are summarized in Table 3.
Protein kinase assays [26]
Buffers. Buffer A: 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 μg
heparin/mL. Buffer C: 60 mM β-glycerophosphate, 15 mM p-nitrophenylphosphate, 25 mM
MOPS (pH 7.2), 15 mM EGTA, 15 mM MgCl2, 1 mM DTT, 1 mM sodium vanadate, 1 mM
phenylphosphate.
Kinase activities were assayed in buffer A or C at 30˚C at a final ATP concentration of
15 μmol/L. Blank values were subtracted and activities were expressed in percent of the maxi-
mal activity, i.e. in the absence of inhibitors. Controls were performed with appropriate dilu-
tions of DMSO. The GS-1, CKS, CDK7/9 tide and RS peptide substrates were obtained from
Proteogenix (Oberhausbergen, France).
CDK1/cyclin B (M phase starfish oocytes, native), CDK2/cyclin A and CDK5/p25 (human,
recombinant) were prepared as previously described [33]. Their kinase activity was assayed in
buffer A, with 1 mg histone H1/mL, in the presence of 15 μmol/L [γ-33P] ATP (3,000 Ci/mmol;
10 mCi/mL) in a final volume of 30 μL. After 30 min incubation at 30˚C, the reaction was
stopped by harvesting onto P81 phosphocellulose supernatant (Whatman) using a FilterMate
harvester (Packard) and washing in 1% phosphoric acid. Scintillation fluid was added and the
radioactivity measured in a Packard counter.
CDK9/cyclin T (human, recombinant, expressed in insect cells) was assayed as described for
CDK1/cyclin B, but using CDK7/9 tide (YSPTSPSYSPTSPSYSPTSPSKKKK) (8.1 μg/assay)
as a substrate.
GSK-3 (porcine brain, native, affinity purified on axin1-sepharose beads) was assayed, as
described for CDK1 with 0.5 mg BSA /mL + 1 mM DTT and using a GSK-3 specific substrate
(GS-1: YRRAAVPPSPSLSRHSSPHQSpEDEEE) (pS stands for phosphorylated serine) [59].
CK1δ/ε (porcine brain, native, affinity purified on axin2-sepharose beads) was assayed as
described for CDK1 but in buffer C and using 25 μM CKS peptide (RRKHAAIGpSAYSITA),
a CK1-specific substrate[60].
CLK1, 2, 3 and 4 (mouse, recombinant, expressed in E. coli as GST fusion proteins) were
assayed as described for CDK1/cyclin B with 0.5 mg BSA /mL + 1 mM DTT and RS peptide
(GRSRSRSRSRSR) (1μg/assay) as a substrate.
DYRK1A, 1B, 2, 3 (human, recombinant, expressed in E. coli as GST fusion proteins),
CLK1, 2, 3, and 4 (mouse, recombinant, expressed in E. coli as GST fusion proteins) were
assayed in Buffer A (supplemented extemporaneously with 0.15 mg BSA/mL + 1 mM DTT)
with 1 μg of RS peptide (GRSRSRSRSRSR) as a substrate.
All data points for construction of dose response curves were recorded in triplicate. Typi-
cally, the standard deviation of single data points was below 10%.
Cell culture
HT-29 colon carcinoma cells, MDA-MB-231 breast cancer cells, MCF-7 breast carcinoma cells
(all supplied by Leibniz Institute DSMZ—German Collection of Microorganisms and Cell Cul-
tures, Braunschweig, Germany) were maintained in Dulbecco’s Modified Eagle Medium (4.5 g/L
D-glucose, L-glutamine, pyruvate), which was supplemented with gentamycin (50 mg/L) and
fetal bovine serum superior, standardized (Biochrom GmbH, Berlin) (10% v/v), and were pas-
saged once a week. RC-124 healthy human kidney cells (supplied by CLS Cell Lines Service
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GmbH, Eppelheim, Germany) were maintained in McCoy’s 5A (modified, with L-glutamine)
medium which was supplemented with gentamycin (50 mg/L) and fetal bovine serum superior,
standardized (Biochrom GmbH, Berlin) (10% v/v), and were also passaged once a week. For
experiments with RC-124 cells, microtiter plates had been pretreated in the following way: 30 μL
of a sterilized gelatine solution (1.5% (m/V)) were added to each well of flat bottom 96-well plates,
the plates were covered with their lids, incubated for 1h at 37˚C, the excess solution was removed,
the wells were washed with PBS 7.4 pH, and the new cell-culture medium was added.
Crystal violet proliferation assay
The antiproliferative effects were determined according to a routinely used method. In short: a
volume of 100 μL of HT-29 cells (2565 cells/mL), MDA-MB-231 cells (4120 cells/mL), MCF-7
cells (4840 cells/mL) or RC-124 cells (1460 cells/mL) was transferred into the wells of 96-well
plates (note: for RC-124 pretreated plates were used, see above) and incubated at 37˚C/5% CO2
for 72 h (MCF-7, MDA-MB-231, RC-124) or 48 h (HT-29). Stock solutions of 8c in DMSO were
prepared and diluted with the respective cell culture medium to graded concentrations (final con-
centration of DMF: 0.1% v/v). After 72 h (HT-29) or 96 h (MCF-7, MDA-MB-231, RC-124) of
exposure, the cell biomass was determined by crystal violet staining and the IC50 value was deter-
mined as the concentration that caused 50% inhibition of cell proliferation compared to an
untreated control. Results were calculated as the mean values of three independent experiments.
Synthesis of test compounds
General. In general, starting materials were purchased from Acros Organics (Geel, Bel-
gium) or Sigma-Aldrich (Steinheim, Germany). 7-Aminoisoindolin-1-one (10a) was pur-
chased from Enamine (Monmouth, U.S.A). Solvents were used as commercially available
grades for synthesis, with the exception of THFand CH2Cl2 which were dried and purified by
published methods [61].
Melting points (mp) were determined on an electric variable heater (Electrothermal IA 9100,
Bibby Scientific, Stone, United Kingdom) in open glass capillaries. IR-spectra were recorded as
KBr discs on a Thermo Nicolet FT-IR 200 (Thermo Nicolet, Madison, WI, USA). 1H-NMR-sp-
ectra and 13C-NMR-spectra were recorded on the following instruments: Bruker Avance DRX-
400, Bruker Avance III-400 and Bruker Avance II-600 (Bruker Corporation, Billerica, MA,
USA); internal standard tetramethylsilane; signals in ppm (δ scale). Signals in 13C spectra were
assigned based on the results of 13C DEPT135 experiments (NMR Laboratories of the Chemical
Institutes of the Technische Universita¨t Braunschweig). Elemental analyses were determined on
a CE Instruments FlashEA 1112 Elemental Analyser (Thermo Quest) (Thermo Quest, San Jose,
CA, USA). Mass spectra were recorded on a Finnigan-MAT 95 (Thermo Finnigan MAT, Bre-
men, Germany). Accurate measurements were conducted according to the peakmatch method
using perfluorokerosene (PFK) as an internal mass reference; (EI)-MS: ionisation energy 70 eV
(Department of Mass Spectrometry of the Chemical Institutes of the Technische Universita¨t
Braunschweig). TLC: Polygram Sil G/UV254, 40 x 80 mm, (Macherey-Nagel, Du¨ren, Germany),
visualization by UV-illumination (254 nm and 366 nm). Purity was determined by HPLC using
the following devices and settings: isocratic elution: Elite LaChrom (Merck/Hitachi), Pump L-
2130, autosampler L-2200, Diode Array Detector L-2450, organizer box L-2000; column: Merck
LiChroCART 125–4, LiChrosphere 100, RP 18, 5 μm; flow rate 1.000 mL/min, volume of injec-
tion: 10 μL; detection (DAD) at 254 and 280 nm; AUC-%-method.; time of detection 15 min, net
retention time (tN), dead time (tm) related to DMSO; gradient elution: Elite LaChrom (Merck,
Darmstadt, Germany), Pump L-2130, autosampler L-2200, UV Detector L-2400, organizer box
L-2000; column: Merck LiChroCART 125–4, LiChrosphere 100, RP 18, 5 μm; flow rate 1.000
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mL/min, volume of injection: 10 μL; detection at 254 nm; AUC-%-method.; net retention time
(tN), dead time (tm) related to DMSO. For all gradient runs, mixtures of ACN and water were
used as specified for particular compounds. Preparation of H2O+(Et3NH)2SO4-buffer (pH 2.6)
for isocratic HPLC: triethylamine (20.0 mL) and sodium hydroxide (242 mg) are dissolved in
water to 1 L. The solution is adjusted to pH 2.6 by addition of sulfuric acid. Absorption maxima
(λmax) were extracted from the spectra recorded by the DAD in the HPLC peak maxima in iso-
cratic runs (software: EZ Chrom Elite Client/server version 3.1.3.). HPLC gradient 1: (acetoni-
trile/water) 0-10 min (10/90!70/30, linear), 10 min-10.5 min (70/30!90/10, linear), 10.5 min-
16.5 min (90/10); HPLC gradient 2: (acetonitrile/water) 0-2 min (10/90), 2 min-12 min (10/
90!90/10, linear), 12 min-22 min (90/10).
7-Amino-4-bromoisoindolin-1-one (10b). 7-Aminoisoindolin-1-one (10a, 148 mg, 1.00
mmol) was suspended in dichloromethane (8 mL) and cooled to -7˚C. N-Bromosuccinimide
(178 mg, 1.00 mmol) was added and the mixture was stirred for 1h. Na2S2O3 (2.3 mL, 10%)
was added and stirring continued for another 20 min. The aqueous phase was extracted with
CH2Cl2 (2 x 10 mL), the combined organic phases were washed with water (3 x 10 mL) and
brine (10 mL) and dried over Na2SO4. The solvent was evaporated under vacuum. The raw
product was used without further purification.
Light brown crystals, 177 mg (78%). 1H-NMR (DMSO-d6, 400 MHz): δ 4.14 (s, 1H, CH2),
6.20 (s, 2H, amine-NH), 6.55 (d, 1H, J = 8.6 Hz), 7.32 (d, 1H, J = 8.6 Hz), 8.38 (s, 1H, pyrroli-
done-NH); 13C NMR (DMSO-d6, 101 MHz): δ 45.35 (CH2); 115.01, 134.86 (CH); 100.37,
115.75, 144.46, 146.38, 171.53 (C); C8H7BrN2O (227.1).
7-Amino-4-chloroisoindolin-1-one (10c). 7-Aminoisoindolin-1-one (10a, 296 mg, 2.00
mmol) was dissolved in acetonitrile (20 mL) and heated to 60˚C. After the addition of N-chlor-
osuccinimide (294 mg, 2.20 mmol) the mixture was refluxed for 3.5 h. The mixture was then
partitioned between ethyl acetate (30 mL) and NaOH solution (5%, 2 x 40 mL). The organic
phase was washed with water (40 mL), dried over Na2SO4 and the solvent was evaporated
under vacuum. Further usage as raw product.
Yellow-brown solid, 303 mg (81%). 1H NMR (DMSO-d6, 400 MHz): δ 4.21 (s, 2H, pyrroli-
done-CH2), 6.16 (s, 2H, NH2), 6.59 (d, 1H, J = 8.6 Hz), 7.21 (d, 1H, J = 8.6 Hz), 8.38 (s, 1H, pyr-
rolidone-NH); 13C NMR (DMSO-d6, 101 MHz): δ 43.75 (CH2), 114.54, 132.12 (CH), 112.82,
115.34, 142.25, 145.93, 171.43 (C); C8H7ClN2O (282.6).
7-Amino-2-methylisoindolin-1-one (10d). 7-Aminoisoindolin-1-one (10a, 74 mg, 0.5 mmol)
was dissolved in dry THF (5 mL) under N2 atmosphere. At room temperature potassium tert-
butylat (56 mg, 0.5 mmol) was added and the mixture was stirred for 1 h. Subsequently iodo-
methane (310 μL, 5.00 mmol) was added and stirring continued for 24 h. After the addition of
silica gel (1.5 g) the solvent was evaporated under vacuum. Purification was done by column
chromatography (ethyl acetate).
Yellow solid, 44 mg (54.3%), mp .1H-NMR (DMSO-d6, 400 MHz): δ 2.98 (s, 3H, CH3), 4.30
(s, 2H, CH2), 6.01 (br s, 2H, amine-NH), 6.54 (dd, 1H, J = 0.8 Hz, 8.0 Hz), 6.61 (dd, 1H, J = 0.9
Hz, 7.4 Hz), 7.17 (dd, 1H, J = 7.3 Hz, 8.1 Hz); 13C-NMR (DMSO-d6, 101 MHz): δ 29.10 (CH3),
52.14 (CH2); 113.53, 116.28, 132.68 (CH); 117.61, 142.90, 143.55, 168.15 (C); C9H10N2O
(213.7).
Synthesis of aryl hydrazinium chlorides 11a-11d. A solution of NaNO2 (76 mg, 1.1
mmol) in water (3 mL) was added dropwise to a cooled (< 0˚C) suspension of the respective
7-aminoisoindolin-1-one (10a, 10d, 1.00 equiv.; 10b-c, raw products used as obtained from
the synthesis described above) in HCl (37%, 8 mL). After the mixture had cleared it was added
to a cooled suspension of SnCl2 x 2H2O (677 mg, 3.00 mmol) in HCl (37%, 8 mL). The result-
ing suspension was then stirred at< 0˚C for 30 min and afterwards stored at 8˚C for 12 h to
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allow precipitation. The precipitate was isolated by vacuum filtration and washed with petrol
ether. Without further purification the hydrazine was used for the following reactions.
2-(3-Oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a). From 7-aminoisoindolin-1-one
(10a, 296 mg, 2.00 mmol), sodium nitrite (166 mg, 2.20 mmol) and tin(II)chloride-dihydrate
(1354 mg, 6.00 mmol). Brown powder, 670 mg raw product. 1H NMR (DMSO-d6, 400 MHz):
δ 4.44 (s, 2H, CH2), 7.03–7.10 (m, 1H), 7.10–7.17 (m, 1H), 7.46–7.56 (m, 1H), 8.54 (s, 1H, pyr-
rolinone-NH), 9.03 (s, 1H, NH), 10.48 (br s, 3H, NH3
+); 13C NMR (DMSO-d6, 101 MHz): δ
(ppm) 45.81 (CH2); 113.34, 116.45, 132.96 (CH); 117.59, 143.66, 146.13, 171.17 (C);
C8H10ClN3OxH2O (217.7).
2-(7-Bromo-3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11b). From 7-amino-4-bromoi-
soindolin-1-one (10b, 456 mg, 2.00 mmol), sodium nitrite (166 mg, 2.20 mmol) and tin(II)
chloride-dihydrate (1354 mg, 6.00 mmol). Beige solid, 690 mg raw product. 1H NMR (DMSO-
d6, 400 MHz): δ 4.35 (s, 2H, CH2), 7.08 (d, 1H, J = 8.6), 7.72 (d, 1H, J = 8.6), 8.67 (br s, 1H, pyr-
rolidone-NH), 9.21 (s, 1H, hydrazine-NH), 10.66 (s, 3H, hydrazine-NH3
+); 13C NMR (DMSO-
d6, 101 MHz): δ 46.50 (CH2); 115.75, 135.45 (CH); 107.93, 119.38, 143.11, 145.34, 170.34 (C);
C8H9BrClN3O (278.5).
2-(7-Chloro-3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11c). From 7-amino-4-chloroi-
soindolin-1-one (10c, 457 mg, 2.50 mmol), sodium nitrite (190 mg, 2.75 mmol) and tin(II)
chloride-dihydrate (1692 mg, 7.50 mmol). Beige solid, 640 mg raw product. 1H NMR (DMSO-
d6, 400 MHz): δ 4.39 (s, 2H, pyrrolidone-CH2), 7.08 (d, 1H, J = 8.7 Hz), 7.55 (d, 1H, J = 8.6
Hz), 8.39 (s, 1H, pyrrolidone-NH), 9.04 (s, 1H, hydrazine-NH), 9.95 (br s, 3H, hydrazinium-
NH3
+); 13C NMR (DMSO-d6, 101 MHz): δ 44.71 (CH2), 114.38, 132.54 (CH), 118.23, 118.38,
118.61, 142.95, 170.73 (C); C8H9Cl2N3O (234.1).
2-(2-Methyl-3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11d). From 7-amino-2-methyli-
soindolin-1-one (10d, 174 mg, 1.07 mmol), sodium nitrite (81 mg, 1.18 mmol) and tin(II)chlo-
ride-dihydrate (724 mg, 3.21 mmol). Brown solid, 455 mg raw product. IR (KBr): 3434 cm-1
(NH), 3297 cm-1 (NH), 1605 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 3.08 (s, 3H,
CH3), 7.06 (d, 1H, J = 8.1 Hz), 7.16 (d, 1H, J = 7.5 Hz), 7.51 (dd, 1H, J = 7.5 Hz, 8.2 Hz), 8.5 (br
s, 1H, hydrazine-NH), 10.51 (s, 3H, hydrazine-NH); 13C NMR (DMSO-d6, 101 MHz): δ 29.10
(CH3), 52.14 (CH2); 113.53, 116.28, 132.68 (CH); 117.61, 142.90, 143.55, 168.15 (C);
C9H10N2O (213.7).
Synthesis of compounds 8a, 8c, 8d, 8e, 8i, 8k, 12a-d. The corresponding 2-(3-oxoisoin-
dolin-4-yl)hydrazin-1-ium chloride (1.00 equiv) was dispersed in 10 mL acetic acid together
with sodium acetate (83 mg, 1.0 equiv) and an appropriately substituted phenylacetaldehyde,
or the corresponding dimethyl acetal, or an appropriately substituted ketone (1.00–1.50
equiv). The mixture was heated at 90–100˚C for 3.5 h. After cooling and addition of aqueous
sodium acetate solution (5%, 20 mL), the mixture was partitioned between water (30 mL) and
ethyl acetate (5 x 30 mL). The combined organic layers were dried over Na2SO4. After addition
of silica gel (1.5 g), the solvent was evaporated. Purification by column chromatography (tolu-
ene, ethyl acetate, acetic acid) and recrystallization from ethanol.
3-Phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8a). From phenylacetaldehyde
dimethylacetal (665 μL, 4.00 mmol), 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a,
1340 mg, raw product obtained as described above) and sodium acetate (328 mg, 4.00 mmol).
Yellow solid, mp 294–295˚C, 307 mg (31%). IR (KBr): 3435 cm-1 (NH), 3200 cm-1, 1661 cm-1
(C = O); 1H NMR (DMSO-d6, 400 MHz): δ 4.47 (s, 2H, CH2), 7.22–7.32 (m, 2H), 7.40–7.50
(m, 2H), 7.61 (d, 1H, J = 2.6 Hz), 7.66–7.75 (m, 2H), 8.07 (d, 1H, J = 8.2 Hz), 8.5 (s, 1H, pyrroli-
done-NH), 11.8 (s, 1H, indole-NH); 13C NMR (DMSO-d6, 101 MHz): δ 45.62 (CH2), 114.71,
122.78, 123.93, 125.63, 126.85 (2C), 128.82 (2C) (CH), 116.34, 116.59, 125.28, 130.85, 135.26,
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139.56, 170.44 (C); C16H12N2O (248.3); MS (EI) m/z 248.1 [M]+, HRMS (EI): m/z [M-H]+
calcd 247.08659, obsd 247.08545.
3-(3-Chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8c). From 3-chlorophenylace-
taldehyde (232 mg, 1.50 mmol), 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a, 335
mg, raw product obtained as described above) and sodium acetate (82 mg, 1.0 mmol). Red
brown powder, mp 215–216˚C, 57 mg (20%); IR (KBr): 3445 cm-1, 3423 cm-1 und 3362 (NH),
1660 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 4.48 (s, 2H, CH2), 7,31 (m, 2H), 7.47 (t,
1H, J = 7.9 Hz), 7.71 (m, 3H), 8.07 (d, 1H, J = 8.2 Hz), 8.48 (s, 1H, pyrrolinone-NH), 11.91 (s,
1H, indole-NH); 13C NMR (DMSO-d6, 101 MHz): δ 45.63 (CH2); 115.07, 122.58, 124.96,
125.02, 125.33, 126.17, 130.63 (CH); 114.83, 116.72, 124.98, 130.89, 133.54, 137.53, 139.75,
170.33 (C); C16H11ClN2O (282.7); MS (EI) m/z 282 [M]+.; HRMS (EI) m/z [M-H]+ calcd
281.04762, obsd 281.04697.
3-(4-Chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8d). From 4-chlorophenyla-
cetaldehyde (155 mg, 1.00 mmol), 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a, 335
mg, raw product obtained as described above) and sodium acetate (82 mg, 1.0 mmol). White-
yellow solid, mp 255–257˚C, 59 mg (21%); IR (KBr): 3429 cm-1 and 3217 cm-1 (NH), 1662 cm-
1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 4.47 (s, 2H, CH2), 7.28 (d, 1H, J = 8.2 Hz), 7.48
(d, 2H, J = 8.5 Hz), 7.67 (d, 1H), 7.74(d, 2H, J = 8.5 Hz), 8.06 (d, 1H, J = 8.2 Hz), 8.46 (s, 1H,
pyrrolinone-NH), 11.86 (s, 1H, indole-NH); 13C NMR (DMSO-d6, 101 MHz): δ 45.62 (CH2);
114.91, 122.65, 124.46, 128.39, 128.74 (CH); 115.04, 116.67, 125.04, 129.97, 130.88, 134.19,
139.69, 170.36 (C); C16H11ClN2O (282.7); MS (EI) m/z 282 [M]+.; HRMS (EI) m/z [M]+. calcd
282.05544, obsd 282.05486.
3-(3,4-Dichlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8e). From 3,4-dichlorophe-
nyl-acetaldehyde (284 mg, 1.50 mmol), 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a,
335 mg, raw product obtained as described above) and sodium acetate (82 mg, 1.0 mmol).
White-yellow solid, mp 258–259˚C, 30 mg (10%); IR (KBr): 3345 cm-1 and 3356 cm-1 (NH),
1672 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 4.48 (s, 2H, CH2), 7.31 (d, 1H, J = 8.3),
7.67 (d, 1H, J = 8.4), 7.74 (dd, 1H, J = 8.4, 2.1), 7.80 (d, 1H, J = 2.7), 7.94 (d, 1H, J = 2.1), 8.07 (d,
1H, J = 8.3), 8.46 (s, 1H, pyrrolinone-NH), 11.95 (br s, 1H, indole-NH); 13C NMR (DMSO-d6,
101 MHz): δ (ppm) = 45.62 (CH2); 115.19, 122.51, 125.41, 126.73, 128.02, 130.90 (CH); 113.78,
116.76, 124.81, 127.65, 130.81, 131.46, 136.17, 139.82, 170.25 (C); C16H10Cl2N2O (317.18); MS
(EI): m/z 316 [M]+.; HRMS (EI): m/z [M]+. calcd 316.01647, obsd 316.01636.
3-(3-Methylphenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8i). From 3-methylphenyla-
cetaldehyde (141 mg, 1.10 mmol), 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a, 335
mg, raw product obtained as described above) and sodium acetate (82 mg, 1.0 mmol). Light
yellow powder, mp 231–232˚C, 36 mg (14%); IR (KBr): 3424 cm-1 and 3261 cm-1 (NH), 1682
cm-1 (C = O); 1H NMR (DMSO-d6, 600 MHz): δ 2.38 (s, 3H, CH3) 4.47 (s, 2H, CH2), 7.08 (d,
1H, J = 7.4 Hz), 7.27 (d, 1H, J = 8.3 Hz), 7.33 (t, 1H, J = 7.6), 7.50 (m, 2H), 7.58 (d, 1H, J = 2.5
Hz), 8.07 (d, 1H, J = 8.3 Hz) 8.45 (s, 1H, pyrrolinone-NH), 11.75 (s, 1H, indole-NH); 13C
NMR (DMSO-d6, 151 MHz): δ 21.16 (CH3); 45.62 (CH2); 114.64, 122.86, 123.84, 123.98,
126.33, 127.49, 128.70 (CH); 130.83, 135.15, 137.85, 139.51, 170.46 (C); C17H14N2O (262.11);
MS (EI): m/z 262 [M]+.; HRMS (EI): m/z [M]+. calcd 262.11006, obsd 262.10972.
2-Methyl-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8k). From phenylacetone
(270 μL, 2.00 mmol), 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a, 670 mg, raw
product obtained as described above) and sodium acetate (164 mg, 2.0 mmol). Red brown
powder, mp 245–247˚C, 102 mg (19%); IR (KBr): 3420cm-1 (NH), 1684cm-1(C = O), 1637cm-
1; 1H NMR (DMSO-d6, 400 MHz): 2.50 (s, 3H, CH3), 4.44 (s, 2H, CH2), 7.16 (d, 1H, J = 8.1
Hz), 7.25–7.36 (m, 1H), 7.43–7.53 (m, 4H), 7.72 (d, 1H, J = 8.1 Hz), 8.38 (s, 1H, pyrrolidone-
NH), 11.57 (s, 1H, indole-NH); 13C NMR (DMSO-d6, 101 MHz): δ 12.12 (CH3); 45.51 (CH2);
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114.14, 121.37, 125.53, 128.54, 128.89 (CH); 112.84, 115.67, 127.22, 129.38, 133.38, 135.11,
138.50, 170.54 (C); C17H14N2O (262.3); MS (EI) m/z 262.1 [M]+., HRMS (EI) m/z [M]+. calcd
262.11006, obsd 262.10970.
2-Ethyl-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8l). From 1-phenylbutan-2-one
(300 μL, 2.00 mmol), 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a, 670 mg, raw
product obtained as described above) and sodium acetate (164 mg, 2.0 mmol). Yellow needles,
mp 165–170˚C, 131 mg (24%); IR (KBr): 3192 cm-1 (NH), 1671 cm-1 (C = O); 1H NMR
(DMSO-d6, 400 MHz): δ 1.26 (t, 3H, J = 7.4 Hz, ethyl-CH3), 2.84 (q, 2H, J = 7.5, ethyl-CH2),
4.44 (s, 2H, CH2), 7.16 (d, 2H, J = 8.1 Hz), 7.26–7.36 (m, 1H), 7.41–7.53 (m, 4H), 7.67 (d, 1H,
J = 8.1 Hz), 8.40 (s, 1H, pyrrolidone-NH), 11.56 (s, 1H, indole-NH); 13C NMR (DMSO-d6, 101
MHz): δ 15.15 (CH3); 19.04, 45.52 (CH2); 114.12, 121.60, 125.77, 128.62 (2C), 129.06 (2C)
(CH); 112.45, 115.78, 127.33, 129.52, 135.11, 138.75, 139.28, 170.57 (C); C18H16N2O (276.3);
MS (EI) m/z 276.1 [M]+., HRMS (EI) m/z [M]+. calcd 276.12571, obsd 276.12606.
5-Bromo-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (12a). From phenylacetalde-
hyde dimethylacetal (500 μL, 3.00 mmol), 2-(7-bromo-3-oxoisoindolin-4-yl)hydrazin-1-ium
chloride (11b, 1035 mg, raw product obtained as described above) and sodium acetate (246
mg, 3.0 mmol). Yellow solid, mp 226–227˚C, 270 mg (28%); IR (KBr): 3449 cm-1, 3424 cm-1
(NH), 1708 cm-1, 1674 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): 4.39 (s, 2H, CH2), 7.24–
7.34 (m, 1H), 7.41–7.51 (m, 2H), 7.65–7.73 (m, 3H), 8.18 (s, 1H), 8.74 (s, 1H, pyrrolidone-
NH), 12.04 (d, 1H, J = 2.9 Hz); 13C NMR (DMSO-d6, 101 MHz): δ 46.40 (CH2); 124.60, 125.47,
125.95, 126.93 (2C), 128.93 (2C) (CH); 107.41, 116.02, 118.30, 127.62, 130.07, 134.49, 138.27,
169.51 (C); C16H11BrN2O (327.18); MS (EI): m/z 326.0 [M]+..
5-Bromo-2-methyl-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (12b). From phenyla-
cetone (230 μL, 1.70 mmol), 2-(7-bromo-3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11b,
587 mg, raw product obtained as described above) and sodium acetate (139 mg, 1.7 mmol).
Light yellow needles, mp 255–256˚C, 113 mg (19%); IR (KBr): 3418 cm-1, 3216 cm-1 (NH),
1691 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 2,50 (s, 3H, CH3), 4.35 (s, 2H, CH2),
7.27–7.38 (m, 1H), 7.45–7.54 (m, 4H), 7.79 (s, 1H), 8.68 (s, 1H, pyrrolidone-NH), 11.85 (s, 1H,
indole-NH); 13C NMR (DMSO-d6, 101 MHz): δ 12.15 (CH3), 46.30 (CH2), 123.12, 125.93,
128.72 (2C), 128.92 (2C) (CH), 106.81, 112.56, 117.42, 128.66, 129.69, 134.35, 135.26, 137.10,
169.63 (C); C17H13BrN2O (341.2); MS (EI) m/z 340.0 [M]+., HRMS (EI) m/z [M]+. calcd
340.02058, obsd 340.02053.
5-Chloro-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (12c). From phenylacetalde-
hyde dimethylacetal (415 μL, 2.50 mmol), 2-(7-chloro-3-oxoisoindolin-4-yl)hydrazin-1-ium
chloride (11c, 640 mg, raw product obtained as described above) and sodium acetate (205 mg,
2.5 mmol). White solid, mp 208–210˚C, 101 mg (15%); 1H NMR (DMSO-d6, 400 MHz): 4.45
(s, 2H, CH2), 7.28 (tt, 1H, J = 1.0 Hz, 7.4 Hz), 7.46 (tt, 2H, J = 1.9 Hz, 7.6 Hz), 7.65–7.73 (m,
3H), 8.04 (s, 1H), 8.71 (s, 1H, pyrrolidone-NH), 12.01 (br s, 1H, indole-NH); 13C NMR
(DMSO-d6, 101 MHz): δ 44.79 (CH2); 121.67, 125.57, 125.92, 126.89 (2C), 128.90 (2 C) (CH),
116.15, 118.05, 119.26, 127.05, 129.67, 134.50, 136.44, 169.42 (C); C16H11ClN2O (282.72); MS
(EI): m/z 282.1 [M]+.
7-Methyl-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (12d). From phenylacetalde-
hyde dimethylacetal (166 μL, 1.00 mmol), 2-(2-methyl-3-oxoisoindolin-4-yl)hydrazin-1-ium
chloride (11d, 455 mg, raw product obtained as described above) and sodium acetate (82 mg,
1.0 mmol). Off-white powder, mp. 265–267˚C, 82 mg (31%); IR (KBr): 3306 cm-1(NH), 1659
cm-1 (C = O), 1600 cm-1; 1H NMR (DMSO-d6, 400 MHz): δ 3.13 (s, 3H, CH3), 4.42 (s, 2H,
CH2), 7.24–7.30 (m, 2H), 7.41–7.48 (m, 2H), 7.62 (d, 1H, J = 2.6 Hz), 7.67–7.74 (m, 2H), 8.06
(d, 1H, J = 8.2 Hz), 11.78 (s, 1H, indole-NH); 13C NMR (DMSO-d6, 101 MHz): δ 28.86 (CH3);
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52.06 (CH2); 114.32, 122.45, 124.07, 125.63, 126.84, 128.81 (CH); 116.39, 130.54, 135.19,
136.91, 167.60 (C); C17H14N2O (262,3); MS (EI): m/z 262.1 [M]+.
Synthesis of compounds 8b, 8f, 8j. PdCl2(MeCN)2 (0.13 equiv), p-benzoquinone (0.6
equiv) were suspended in heated tert-butanol (5 mL) at 85˚C. Subsequently water (0.5 equiv)
and the respective styrene (0.50 equiv) were added and then the mixture was stirred at 85˚C for
1 h. Afterwards the mixture was cooled on ice until solid to stop the reaction. In the next step
the mixture was heated again to 30˚C and subsequently the 2-(3-oxoisoindolin-4-yl)hydrazin-
1-ium chloride 11a suspension (raw product obtained as described above, H2SO4 (98%, 0.88
mL), water (1.46 mL) and ethanol (4.39 mL)) was added. The mixture was stirred at 50˚C for
2.5 h. After completion of the reaction, water (20 mL) was added and then the suspension was
extracted with ethyl acetate (5 x 15 mL). The combined organic phases were dried over Na2SO4
and the solvent was evaporated under vacuum mounting the mixture on silica gel (1.5 g). Purifi-
cation was done by column chromatography (toluene/ethyl acetate/acetic acid(5/5/0.5) and
recrystallization from ethanol.
3-(2-Chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8b). From PdCl2(MeCN)2 (7
mg, 25 μmol), p-benzoquinone (125 mg, 1.18 mmol), 2-chlorostyrene (127 μL, 1.00 mmol)
and 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a, 670 mg, raw product obtained as
described above). Beige powder, mp 234–235˚C, 58 mg (21%); IR (KBr): 3439cm-1(NH),
1668cm-1 (C = O); 1H NMR (DMSO-d6, 600 MHz): 4.42 (s, 2H, CH2), 7.23 (d, 1H, J = 8.1 Hz),
7.33–7.39 (m, 1H), 7.43 (dt, 1H, J = 1.4 Hz, 7.5 Hz), 7.51 (d, 1H, J = 2.6 Hz), 7.57 (dd, 1H,
J = 1.7 Hz, 7.6 Hz), 7.60 (dd, 1H, J = 1.3 Hz, 8.0 Hz), 7.66 (d, 1H, J = 8.1 Hz), 8.46 (s, 1H, pyrro-
lidone-NH), 8.87 (br s, 1H, indole-NH); 13C NMR (DMSO-d6, 151 MHz): δ 45.55 (CH2);
114.49, 122.91, 125.64, 127.20, 129.88, 131.93 (CH); 113.27, 116.51, 126.14, 127.99, 129.84,
132.07, 133.35, 139.54, 170.27 (C); C16H11ClN2O (282.7); MS (EI): m/z 282.1 [M]+..
3-(3-Methoxyphenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8f). From PdCl2(MeCN)2
(13 mg, 50 μmol), p-benzoquinone (249 mg, 2.36 mmol), 3-methoxystyrene (275 μL, 2.00
mmol) and 2-(3-oxoisoindolin-4-yl)hydrazin-1-ium chloride (11a, 1340 mg, raw product
obtained as described above). Red solid, mp 207–208˚C, 64 mg (23%); IR (KBr): 3397 cm-1
and 3246 cm-1 (NH), 1670 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 3.83 (s, 3H, CH3),
4.47 (s, 2H, CH2), 6.84 (dd, 1H, J = 8.2, 2.6), 7.20–7.38 (m, 4H), 7.64 (d, 1H, J = 2.6 Hz), 8.07(d,
1H, J = 8.2 Hz), 8.43 (s, 1H, pyrrolinone-NH), 11.77 (s, 1H, indole-NH); 13C NMR (DMSO-d6,
101 MHz): δ 54.72 (CH3); 45.35 (CH2); 111.16, 111.85, 114.48, 118.95, 122.54, 123.93, 129.53
(CH); 116.26, 116.57, 125.26, 130.83, 136.63, 139.54, 159.66 (C); C17H14N2O2 (278.3); MS (EI):
m/z 278.1 [M]+..
3-(3-Nitrophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8j). From PdCl2(MeCN)2 (3 mg,
13 μmol), p-benzoquinone (62 mg, 0.6 mmol), 3-nitrostyrene (70 μL, 0.50 mmol) and 2-(3-oxoi-
soindolin-4-yl)hydrazin-1-ium chloride (11a, 335 mg, raw product obtained as described
above). Yellow solid, mp 237–238˚C (decomposition), 76 mg (26%); IR (KBr): 3401 cm-1, 3280
cm-1 (NH), 1686 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 4.49 (s, 2H, CH2), 7.35 (d,
1H, J = 8.2 Hz), 7.73 (t, 1H, J = 8.0 Hz), 7.90 (d, 1H, J = 2.7 Hz), 8.10 (m, 2H), 8.20 (dt, 1H,
J = 1.3 Hz, 7.9 Hz), 8.48 (t, 1H, J = 2.0 Hz), 8.51 (s, 1H, pyrrolinone-NH), 12.04 (s, 1H, indole-
NH); 13C NMR (DMSO-d6, 101 MHz): δ 45.7 (CH2); 115.4, 120.1, 120.6, 122.3, 125.7, 130.3,
133.1 (CH); 114.1, 116.9, 124.9, 131.0, 137.1, 140.0, 148.4, 170.3 (C); C16H11N3O3(293.8); MS:
(EI) m/z 293.1 [M]+.; HRMS (EI) m/z [M]+. calcd 293.07949, obsd 293.07913. HPLC: 98.7% at
256 nm and 98.9% at 280 nm; tN = 3.6 min, tM(DMSO) = 1.06 min (ACN/H2O = 60/40), HPLC
(Gradient elution: (ACN/H2O) 0-10 min (10/90!70/30, linear), 10 min-10.5 min (70/30!90/
10, linear), 10.5 min-16.5 min (90/10)): 89.4% at 254 nm and 97.2% at 280 nm; tN = 10.6 min.
λmax = 232 nm, 269 nm.
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3-(3-Hydroxyphenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (8g). 3-(3-Methoxyphenyl)-
6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one 8f (167 mg, 0.60 mmol) was dissolved in dry
CH2Cl2 (15 mL) under nitrogen atmosphere. Boron tribromide solution in dichloromethane
(3 mmol, 3 mL, c = 1 M) was added and the mixture was stirred at RT under N2-atmosphere
for 1 h. After adding water (28 mL) and stirring for another hour, the precipitate was filtered
under vacuum. The filtrate was partitioned between water (28 mL) and ethyl acetate (5 x 30
mL). The precipitate was dissolved in the dried organic phases, the solvent evaporated under
vacuum and the precipitate recrystallized from ethanol 80%.
Brown solid, mp 235–236˚C (decomposition), 53 mg (33%); IR (KBr): 3386 cm-1 (NH),
3222 cm-1 (NH), 1656 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 4.47 (s, 2H, CH2), 6.67
(ddd, 1H, J = 1.1 Hz, 2.3 Hz, 8.1 Hz), 7.11 (m, 2H), 7.23 (t, 1H, J = 8.0 Hz), 7.27 (d, 1H, J = 8.2
Hz), 7.53 (d, 1H, J = 2.6 Hz), 8.04 (d, 1H, J = 8.2 Hz), 8.45 (s, 1H, pyrrolidone-NH), 9.39 (s,
1H, phenol-OH), 11.73 (s, 1H, indole-NH); 13C NMR (DMSO-d6, 101 MHz): δ 45.6 (CH2),
112.7, 113.7, 114.6, 117.7, 122.8, 123.7, 129.8 (CH), 116.5, 116.6, 125.3, 130.8, 136.4, 139.5,
157.7, 170.5 (C); C16H12N2O2 (264.3); MS (EI) m/z 264.1 [M]+..
3-(8-Oxo-1,6,7,8-tetrahydropyrrolo[3,4-g]indol-3-yl)phenyl acetate (8h). To a solution of 3-
(3-hydroxyphenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one 8g (151 mg, 0.57 mmol) in pyr-
idine (7 mL) acetic anhydride (60 μL, 0.63 mmol) and 4-dimethylaminopyridine (4-DMAP,
cat, ca. 4 mg) were added. After stirring the mixture for 2 h at room temperature the solvent
was evaporated under vacuum. The crude product was dissolved in ethyl acetate (20 mL) and
extracted with water (20 mL). The aqueous phase was further extracted with ethyl acetate (3 x
20 mL). The combined organic phases were washed with water (2 x 50 mL), dried over
Na2SO4 and the solvent was evaporated under vacuum. Purification by column chromatogra-
phy (ethyl acetate/ethanol/trimethylamine (6/2/2)) and recrystallization from ethanol.
Yellow solid, mp 185–186˚C, 89 mg (29%); IR (KBr): 3337 cm-1 (NH), 3194 cm-1 (NH),
1741 cm-1 (C = O), 1678 cm-1 (C = O); 1H NMR (DMSO-d6, 600 MHz): δ 2.30 (s, 3H, CH3),
4.48 (s, 2H, CH2), 7.01 (ddd, 1H, J = 1.0 Hz, 2.3 Hz, 8.0 Hz), 7.29 (d, 1H, J = 8.1 Hz), 7.45–7.49
(m, 2H), 7.59–7.62 (m, 1H), 7.67 (d, 1H, J = 2.3 Hz), 8.07 (d, 1H, J = 8.2), 8.47 (s, 1H, pyrroli-
done-NH), 11.85 (s, 1H, indole-NH); 13C NMR (DMSO-d6, 151 MHz): δ 21.13 (CH3), 45.55
(CH2), 114.83, 118.77, 119.82, 122.58, 123.99, 124.44, 129.73 (CH), 115.27, 116.59, 124.97,
130.79, 136.64, 139.60, 150.91, 169.21, 170.28 (C); C18H14N2O3 (306.3); MS (EI) m/z 306.1
[M]+., HRMS (EI) m/z [M]+. calcd 306.09989, obsd 306.10020. HPLC: 94.3% at 254 nm and
96,4% bei 280 nm; tN = 4.6, tM(DMSO) = 1,06 min (ACN/H2O = 40/60); HPLC (Gradient elu-
tion: (ACN/H2O) 0-10 min (10/90!70/30, linear), 10 min-10.5 min (70/30!90/10, linear),
10.5 min-16.5 min (90/10)): 93.4% at 254 nm; tN = 9.44 min. λmax = 270 nm, 307 nm.)
Synthesis of compounds 15a-15e. In a round-bottom flask, 3-phenyl-6,7-dihydropyrrolo
[3,4-g]indol-8(1H)-one 8a (1 equiv) was dissolved in acetone (10 mL). At room temperature
potassium tert-butoxide (1 equiv) was added and the mixture was stirred for one hour. The
respective halogen alkane (10 equiv) was added and stirring continued for another 24 h at
room temperature. Purification of the crude product was accomplished by column chromatog-
raphy on silica gel (toluene/ethyl acetate/acetic acid (8/1/0.5)) and recrystallization from tolu-
ene/hexane (2+1).
1-Methyl-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (15a). From 3-phenyl-
6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one 8a (161 mg, 0.65 mmol), potassium tert-butoxide
(73 mg, 0.7 mmol) and iodomethane (405 μL, 6.50 mmol). Yellow solid, mp 255–256˚C, 75 mg
(44%); IR (KBr): 3208 cm-1 (NH), 1686 cm-1 (C = O), 1639 cm-1, 1600 cm-1(C = C, aromatic);
1H NMR (DMSO-d6, 400 MHz): δ 4.40 (s, 3H, CH3), 4.46 (s, 2H, CH2), 7.28 (m, 2H), 7.45 (m,
2H), 7.64 (m, 3H), 8.04 (m, 1H), 8.51 (s, 1H, pyrrolinone-NH); 13C NMR (DMSO-d6, 101
MHz): δ 37.69 (CH3); 45.32 (CH2); 114.84, 123.04, 125.80, 127.04, 128.82, 128.96 (CH); 116.63,
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117.12, 126.30, 132.76, 134.75, 141.32, 170.11 (C); C17H14N2O (262.3); MS (EI) m/z 262.1
[M]+..
1-Ethyl-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (15b). From 3-phenyl-6,7-dihy-
dropyrrolo[3,4-g]indol-8(1H)-one 8a (248 mg, 1.00 mmol), potassium tert-butoxide (112 mg,
1.00 mmol) and iodoethane (805 μL, 10.0 mmol). Yellow needles, mp 198–200˚C, 132 mg
(48%); IR (KBr): 3189 cm-1 (NH), 1679 cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): δ 1.37
(t, 3H, J = 7.0 Hz, ethyl-CH3), 4.46 (s, 2H, CH2), 5.00 (q, 2H, J = 7.0 Hz, ethyl-CH2), 7.22–7.33
(m, 2H), 7.41–7.51 (m, 2H), 7.61–7.69 (m, 2H), 7.72 (s, 1H), 8.05 (d, 1H, J = 8.2 Hz), 8.51 (s,
1H, pyrrolidone-NH); 13C NMR (DMSO-d6, 101 MHz): δ 17.24 (CH3); 44.60, 45.30 (CH2);
114.82, 123.14, 125.78, 127.07, 127.49, 128.81 (CH); 116.89, 116.92, 126.29, 131.76, 134.84,
141.34, 170.11 (C); C18H16N2O (276.3); MS (EI) m/z (%) 276.1 [M]+..
2-(8-Oxo-3-phenyl-7,8-dihydropyrrolo[3,4-g]indol-1(6H)-yl)acetamide (15c). From 3-phenyl-
6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one 8a (186 mg, 0.75 mmol), potassium tert-butoxide
(96 mg, 0.75 mmol) and 2-bromoacetamide (1035 mg, 7.50 mmol). Divergent from the general
intructions purification was conducted by filtration through silica gel (3 cm) and product elu-
tion with ethanol (96%, 300 mL). Light yellow solid, mp 284–285˚C (decomposition), 35 mg
(15%);1H NMR (DMSO-d6, 600 MHz): δ 4.46 (s, 2H, pyrrolidinon-CH2), 5.73 (s, 2H, CH2),
7.04 (s, 1H, amide-NH), 7.25–7.32 (m, 2H), 7.42 (s, 1H, amide-NH), 7.44–7.50 (m, 2H), 7.57
(s, 1H), 7.63–7.68 (m, 2H), 8.06 (d, 1H, J = 8.1 Hz), 8.52 (s, 1H, pyrrolidone-NH); 13C NMR
(DMSO-d6, 101 MHz): δ 45.39, 52.22 (CH2); 114.79, 122.99, 125.76, 126.94 (2C), 128.78 (2C),
128.97 (CH); 116.82, 116.99, 126.14, 133.37, 134.66, 141.14, 170.24, 170.30 (C); C18H15N3O2
(305.3); MS (EI) m/z 305.1 [M]+., HRMS (EI) m/z [M]+. calcd 305.11588, obsd 305.11515.
Ethyl 2-(8-oxo-3-phenyl-7,8-dihydropyrrolo[3,4-g]indol-1(6H)-yl)acetate (15d). From 3-phe-
nyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one 8a (198 mg, 0.80 mmol), potassium tert-butox-
ide (90 mg, 0.8 mmol) and ethyl 2-bromoacetate (885 μL, 8.00 mmol). Yellow solid, mp 226-
227˚C, 69 mg (26%); IR (KBr): 3234 cm-1 (NH), 1739 cm-1 (C = O), 1672 cm-1(C = O), 1634
cm-1 (C = O); 1H NMR (DMSO-d6, 400 MHz): 1.21 (t, 3H, J = 7.1 Hz, CH3), 4.13 (q, 2H,
J = 7.1 Hz, Ethyl-CH2), 4.46 (s, 2H, pyrrolidone-CH2), 5.80 (s, 2H, CH2), 7.24–7.36 (m, 2H),
7.42–7.52 (m, 2H), 7.60–7.70 (m, 3H), 8.07 (d, 1H, J = 8.2 Hz), 8.52 (s, 1H, pyrrolidone-NH);
13C NMR (DMSO-d6, 101 MHz): δ 14.06 (CH3); 45.51, 51.52, 60.48 (CH2); 115.20, 123.13,
126.00, 127.04, 128.65, 128.89 (CH); 117.07, 117.20, 126.35, 133.01, 134.51, 141.23, 169.58,
170.17 (C); C20H18N2O3 (334.4); MS (EI) m/z (%) 334.1 [M]+., HRMS (EI) m/z [M]+. calcd
334.13119, obsd 334.13053.
1,7-Dimethyl-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (15e). From 3-phenyl-
6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one 8a (124 mg, 0.50 mmol), potassium tert-butoxide
(73 mg, 0.7 mmol) and iodomethane (315 μL, 5.00 mmol) dissolved in dry THF (10 mL)
instead of acetone. Purification by preparative HPLC (ACN/H2O (60/40)). Yellow solid, mp
151–152˚C, 36 mg (27%); IR (KBr): 3426 cm-1 (NH), 1661 cm-1 (C = O); 1H NMR (DMSO-d6,
400 MHz): δ 3.12 (s, 3H, CH3), 4.40 (s, 3H, CH3), 4.54 (s, 2H, CH2), 7.28 (m, 2H), 7.46 (m,
2H), 7.65 (m, 3H), 8.04 (d, 1H, J = 8.3); 13C NMR (DMSO-d6, 101 MHz): δ 29,14, 37,59 (CH3);
51,71 (CH2); 114,39, 122,67, 125,77, 126,99, 128,79, 129,08 (CH); 116,57, 116,92, 126,46,
132,36, 134,71, 138,48, 167,21 (C); C18H16N2O (276.3); MS (EI) m/z 276.1 [M]+., HRMS (EI)
m/z [M]+. calcd 276.12571, obsd 276.12532.
2-Bromo-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (16). 3-Phenyl-6,7-dihydropyr-
rolo[3,4-g]indol-8(1H)-one (8a, 124 mg, 0.50 mmol) was dispersed in CH2Cl2/acetic acid (6
mL + 2 mL) under nitrogen atmosphere at< 10˚C. NBS (98 mg, 0.6 mmol) was added and the
mixture was stirred for 1.5 h at room temperature. The solvent was evaporated under vacuum,
the crude product was dissolved in ethyl acetate (30 mL) and the solution was extracted with
potassium hydroxide solution (10%, 3 x 15 mL). After washing the organic phase with water
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(30 mL) it was dried over Na2SO4 and the solvent was evaporated under vacuum. Purification
by recrystallization from ethanol 96%.
Light yellow solid, mp 248–250˚C, 47 mg (29%); IR (KBr): 3409 cm-1(NH), 1691 cm-1
(C = O); 1H NMR (DMSO-d6, 400 MHz): δ 4.46 (s, 2H, CH2), 7.24 (d, 1H, J = 8.2 Hz), 7.33–
7.42 (m, 1H), 7.48–7.55 (m, 2H), 7.55–7.21 (m, 2H), 7.73 (d, 1H, J = 8.0 Hz), 8.49 (br s, 1H, pyr-
rolidone-NH), 12.52 (br s, 1H, indole-NH); 13C NMR (DMSO-d6, 101 MHz): δ 45.53 (CH2),
115.33, 121.66, 126.71, 128.59, 129.20 (CH), 109.14, 115.79, 116.14, 126.62, 130.25, 133.08,
140.09, 169.84 (C); C16H11BrN2O (327.2); MS (EI) m/z 326.0[M]+..
Synthesis of compounds 17a-17c. 5-Bromo-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8
(1H)-one (12a) (1 equiv), tetrakistriphenylphosphinpalladium(0) (0.4 equiv), Cs2CO3 (3
equiv) and the respective phenylboronic acid (1.5 equiv) were suspended in toluene/ethanol (2
mL + 1 mL) in a microwave reactor. The reaction was executed using the following parame-
ters: ramp time: 5 min, reaction time: 20 min at 150˚C, irradiation: 200 W. After filtering the
crude product over silica gel (3 cm) the solvent was evaporated under vacuum. Purification
was done by recrystallization from ethanol or by preparative HPLC.
3,5-Diphenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (17a). From 5-bromo-3-phenyl-
6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (12a) (131 mg, 0.4 mmol), Tetrakistriphenylpho-
sphin-palladium(0) (4 mg, 3.4 μmol) and Cs2CO3 (254 mg, 0.78 mmol) and phenylboronic
acid (98 mg, 0.8 mmol). White yellow solid, mp 262–263˚C, 18 mg (14%); IR (KBr): 3417 cm-1
(NH), 1688 cm-1 (C = O); 1H NMR (DMSO-d6, 600 MHz): δ 4.56 (s, 2H, CH2), 7.27 (tt, 1H,
J = 1.2 Hz, 7.3 Hz), 7.39 (tt, 1H, J = 1.2 Hz, 7.4 Hz), 7.43–7.52 (m, 4H), 7.63–7.66 (m, 2H), 7.67
(d, 1H, J = 2.5 Hz), 7.71–7.77 (m, 2H), 8.02 (s, 1H), 8.58 (s, 1H, pyrrolidone-NH), 11.85 (d,
1H, J = 2.0 Hz, indole-NH); 13C NMR (DMSO-d6, 151 MHz): δ 45.62 (CH2); 122.29, 124.63,
125.61, 126.85 (2C), 128.21 (2C), 128.65 (2C), 128.81 (2C)(CH); 116.53, 116.87, 126.07, 128.71,
130.39, 135.04, 137.16, 139.74, 170.18 (C); C22H16N2O (324.4); MS (EI) m/z 324.1 [M]+.,
HRMS (EI) m/z [M]+. calcd 324.12571, obsd 324.12541.
5-(2-Fluorophenyl)-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (17b). From 5-bromo-
3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (12a) (196 mg, 0.60 mmol), tetrakis-tri-
phenylphosphinpalladium(0) (28 mg, 0.024 mmol), Cs2CO3 (586 mg, 1.80 mmol) and 2-fluoro-
phenylboronic acid (126 mg, 0.90 mmol). Yellow solid, mp 136-139˚C, 11mg (5.4%); IR (KBr):
3417 cm-1 (NH), 3262 cm-1 (NH), 2922 cm-1, 1685 cm-1 (C = O); 1H NMR (DMSO-d6, 600
MHz): δ 4.36 (s, 2H, CH2), 7.24–7.28 (m, 1H), 7.30–7.39 (m, 2H), 7.41–7.51 (m, 3H), 7.61 (td,
1H, J = 1.8 Hz, 7.72 Hz), 7.70 (d, 1H, J = 2.6 Hz), 7.70–7.74 (m, 2H), 7.99 (s, 1H), 8.55 (br s, 1H,
pyrrolidone-NH), 11.93 (d, 1H, J = 2,6 Hz, indole-NH); 13C NMR (DMSO-d6, 151 MHz): δ
(ppm) = 45.21 (d, 5JC,F = 4.47 Hz, C-C-C-C-C-F) (CH2); 115.80 (d,
2JC,F = 22.44, Hz, C-C-F),
123.66, 124.71 (d, 4JC,F = 3.28 Hz, C-C-C-C-F), 124.78, 125.70, 126.86 (2C), 128.83 (2C), 129.55
(d, 3JC,F = 8.13 Hz, C-C-C-F), 131.66 (d,
4JC,F = 3.29 Hz, C-C-C-C-F) (CH); 116.52, 116.69,
122.36, 125.76, 126.76 (d, 2JC,F = 15.46 Hz, C-C-F), 130.61, 134.91, 138.11, 159.05 (d,
1JC,F =
244.03 Hz, C-F), 170.09 (C); C22H15FN2O (342.4); MS (EI) m/z 342.1 [M]+., HRMS (EI) m/z
[M]+. calcd 342.11629, obsd 342.11663.
5-(3-Fluorophenyl)-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (17c). From
5-bromo-3-phenyl-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (12a) (98 mg, 0.3 mmol), tetra-
kistriphenylphosphinpalladium(0) (14 mg, 0.012 mmol), Cs2CO3 (293 mg, 0.90 mmol) and
3-fluorophenylboronic acid (63 mg, 0.3 mmol). Grey solid, mp 246–247˚C, 32 mg (31%); IR
(KBr): 3416 cm-1 (NH), 1690 cm-1 (C = O); 1H NMR (DMSO-d6, 600 MHz): δ 4.48 (s, 1H,
CH2), 7.19–7.24 (m, 1H), 7,27 (tt, 1H, J = 1.2 Hz, 7.4 Hz), 7.42–7.47 (m, 2H), 7.48–7.55 (m,
3H), 7.68 (d, 1H, J = 2.6), 7.73–7.78 (m, 2H), 8.05 (s, 1H), 8.61 (br s, 1H, pyrrolidone-NH),
11.89 (d, 1H, J = 2.7 Hz, indole-NH); 13C NMR (DMSO-d6, 151 MHz): δ 45.53 (CH2); 113.68
(d, 2JC,F = 20.75 Hz, C-C-F), 114.98 (d,
2JC,F = 21.53 Hz, C-C-F), 122,53, 124.48 (d,
4JC,F = 2.55
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Hz, C-C-C-C-F), 124.82, 125.68, 126.92 (2C), 128.84 (2C), 130.55 (d, 3JC,F = 8.66 Hz, C-C-C-F)
(CH); 116.69, 116.95, 126.04, 127.41 (d, 4JC,F = 1.93 Hz, C-C-C-C-F), 130.63, 134.96, 137.16,
142.22 (d, 3JC,F = 7.95 Hz, C-C-C-F), 162.35 (d,
1JC,F = 243.55 Hz, C-F), 170.10 (C);
C22H15FN2O (342.4); MS (EI): m/z 342.1 [M]+., HRMS (EI) m/z [M]+. calcd 342.11629, obsd
342.11679.
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